ETFs Are Net Sellers of Eli Lilly (LLY) on Nov. 18
This article first appeared on GuruFocus.
ETFs net sold $252.2 million of Eli Lilly (LLY) on Wednesday, even though more funds traded the other way: 39 ETFs bought versus 20 that sold, with the sellers moving larger amounts. The move followed three straight days of net buying, including $141.8 million on Nov. 16 and $97.8 million on Nov. 17. ETF activity turned negative after that run, and the one-day selling streak stands at 1 day.
Track the latest ETF buying and selling trends and search funds in the GuruFocus ETF Screener.
For the full record of ETF and guru buying and selling in LLY, see the LLY guru trades page.
Which ETFs sold LLY on Wednesday?
The largest sellers by dollar value were SPY ($203.8 million), XLV ($56.6 million) and IYH ($17.4 million). In all, 39 ETFs added shares and 20 cut them.
SPY accounted for the bulk of the move, cutting 147,378 shares for a $203.8 million decline in value, a 1.49% reduction in its stake and 1.75% portfolio weight. XLV sold 40,922 shares worth $56.6 million at a 16.88% weight, while IYH trimmed 12,600 shares for $17.4 million at a 16.46% weight; CGUS, SPXL, IVW, SSO and IVV made smaller reductions. Eli Lilly operates in the Healthcare sector’s Drug Manufacturers – General industry with a market cap of $1.27 trillion.
Have ETFs been buying or selling LLY lately?
Over the last 5 reported days, ETFs were net buyers on 3 and net sellers on 2, so the recent trend is mostly buying.
What does LLY do?
Eli Lilly discovers, develops, manufactures, and markets human pharmaceutical products in a single business segment, with medicines sold in approximately 90 countries. Its cardiometabolic health franchise leads the portfolio, anchored by the incretin medicines Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea, alongside Trulicity, Jardiance, and insulins.
Eli Lilly’s trailing-12-month revenue was $86.46 billion, up 46.3% over one year, with gross margin of 83.6% and net margin of 31.9%. The stock trades at a P/E of 44.39, P/B of 31.58 and P/S of 14.14, against a market cap of $1.27 trillion. Its GF Score is 96, GF Value is $1,620.04 versus a price of $1,351.12, dividend yield is 0.46% and the year-to-date return is 26.48%.